Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8756134 | 0.81 | KMT2A (0.52) | KMT2ACA1CA2CA9PRSS1 | |
| SCHEMBL9309031 | 0.78 | KMT2A (0.61) | KMT2ACA1CA2CA9PRSS1 | |
| SCHEMBL6114729 | 0.78 | KMT2A (0.61) | KMT2ACA1CA2CA9PRSS1 | |
| SCHEMBL6929134 | 0.77 | KMT2A (0.47) | KMT2ACA1CA2CA9PRSS1 | |
| SCHEMBL10405155 | 0.77 | KMT2A (0.55) | KMT2ACA1CA2CA9PRSS1 | |
| SCHEMBL2439083 | 0.76 | CA2 (0.61) | KMT2ACA1CA2CA9PRSS1 | |
| SCHEMBL7619550 | 0.75 | KMT2A (0.57) | KMT2ACA1CA2CA9PRSS1 | |
| Benzene SCHEMBL28852658 | 0.75 | KMT2A (0.57) | KMT2ACA1CA2CA9PRSS1 | |
| SCHEMBL354454 | 0.75 | KMT2A (0.57) | KMT2ACA1CA2CA9PRSS1 | |
| SCHEMBL3978412 | 0.75 | CA2 (0.59) | KMT2ACA1CA2CA9PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285620-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | Afferent Pharmaceuticals, Inc. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240158356-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4215182-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | Afferent Pharmaceuticals Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20220143015-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | Afferent Pharmaceuticals, Inc. (US) | 2022-05-12 | — | — | US | disclosed |
| EP-3981406-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS | Afferent Pharmaceuticals Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11260056-B2 | Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough | Afferent Pharmaceuticals, Inc. (US) | 2022-03-01 | — | — | US | disclosed |
| EP-3865134-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X 2/3 RECEPTOR MODULATORS FOR TREATMENT OF ACUTE AND SUB-ACUTE COUGH, URGE TO COUGH AND CHRONIC COUGH, IN RESPIRATORY DISEASES | Afferent Pharmaceuticals Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210008071-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20200108065-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS | Afferent Pharmaceuticals, Inc. (US) | 2020-04-09 | — | — | US | disclosed |
| US-10543211-B2 | Methods and compositions for treating diseases and conditions | Afferent Pharmaceuticals, Inc. (US) | 2020-01-28 | — | — | US | disclosed |
| EP-3035932-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X 2/3 RECEPTOR MODULATORS FOR TREATMENT OF ACUTE, SUB-ACUTE OR CHRONIC COUGH | Afferent Pharmaceuticals Inc. (US) | 2016-06-29 | — | — | EP | disclosed |
| CN-105682659-A | Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of acute, sub-acute or chronic cough | 传入制药公司 | 2016-06-15 | — | — | CN | disclosed |
| US-9284279-B2 | Substituted pyrimidines for treatment of acute cough, chronic cough and urge to cough | Afferent Pharmaceuticals, Inc. (US) | 2016-03-15 | — | — | US | disclosed |
| WO-2016004358-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS | Afferent Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2015027212-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X 2/3 RECEPTOR MODULATORS FOR TREATMENT OF ACUTE, SUB-ACUTE OR CHRONIC COUGH | AFFERENT PHARMACEUTICALS INC. (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057299-A1 | Methods of Using Diaminopyrimidine P2X3 and P2X 2/3 Receptor Modulators for Treatment of Acute and Sub-Acute Cough, Urge to Cough and Chronic Cough, in Respiratory Diseases | Afferent Pharmaceuticals, Inc. | 2015-02-26 | — | — | US | disclosed |
| CN-101300012-B | Use of Diaminopyrimidine as P2X3 and P2x2/3 modulators in preparing medicine for treating respiratory diseases | HOFFMANN LA ROCHE | 2011-09-14 | — | — | CN | disclosed |
| CN-101300012-A | Diaminopyrimidine as P2X3 and P2x2/3 modulators | ROCHE PALO ALTO LLC (CH) | 2008-11-05 | — | — | CN | disclosed |
| US-4029809-A | Method of protecting plants from pathogens with cyanomethyl aryl sulfonates | PENNWALT CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
| US-3974292-A | Cyanoalkyl sulfonates for the control of fungus growth | SCM CORPORATION (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108065-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS | P2RX3, P2RX2, P2RX5 | KMT2A 1567/4885CA1 1396/4885CA2 317/4885 |
| US-10543211-B2 | Methods and compositions for treating diseases and conditions | P2RX3, P2RX2, P2RX5 | KMT2A 1567/4885CA1 1396/4885CA2 317/4885 |
| US-20210008071-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | KMT2A 3752/4885CA1 3217/4885CA2 897/4885 |
| US-20220143015-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | P2RX3, P2RX2, P2RX5 | KMT2A 3669/4885CA1 3432/4885CA2 514/4885 |
| US-20240158356-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KMT2A 3706/4885CA1 2902/4885CA2 1106/4885 |
| US-20240285620-A1 | DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH | P2RX3, P2RX2, P2RX5 | KMT2A 3669/4885CA1 3432/4885CA2 514/4885 |
| US-20150057299-A1 | Methods of Using Diaminopyrimidine P2X3 and P2X 2/3 Receptor Modulators for Treatment of Acute and Sub-Acute Cough, Urge to Cough and Chronic Cough, in Respiratory Diseases | P2RX3, P2RX2, P2RX5 | KMT2A 2980/4885CA1 2658/4885CA2 510/4885 |
| US-11260056-B2 | Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough | P2RX3, P2RX2, P2RX5 | KMT2A 3669/4885CA1 3432/4885CA2 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.